Joaquín Martínez‐López

25.4k total citations
418 papers, 6.1k citations indexed

About

Joaquín Martínez‐López is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Joaquín Martínez‐López has authored 418 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 238 papers in Hematology, 144 papers in Oncology and 143 papers in Molecular Biology. Recurrent topics in Joaquín Martínez‐López's work include Multiple Myeloma Research and Treatments (151 papers), CAR-T cell therapy research (58 papers) and Chronic Myeloid Leukemia Treatments (56 papers). Joaquín Martínez‐López is often cited by papers focused on Multiple Myeloma Research and Treatments (151 papers), CAR-T cell therapy research (58 papers) and Chronic Myeloid Leukemia Treatments (56 papers). Joaquín Martínez‐López collaborates with scholars based in Spain, United States and France. Joaquín Martínez‐López's co-authors include F.J. Salvador, Juan José Lahuerta, Rosa Ayala, Jesús F. San Miguel, María‐Victoria Mateos, Alejandra Leivas, Albert Oriol, Joan Bladé, Raúl Payri and J.‐V. Romero and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Joaquín Martínez‐López

378 papers receiving 6.0k citations

Peers

Countries citing papers authored by Joaquín Martínez‐López

Since Specialization

Citations

This map shows the geographic impact of Joaquín Martínez‐López's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joaquín Martínez‐López with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joaquín Martínez‐López more than expected).

Fields of papers citing papers by Joaquín Martínez‐López

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joaquín Martínez‐López. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joaquín Martínez‐López. The network helps show where Joaquín Martínez‐López may publish in the future.

Co-authorship network of co-authors of Joaquín Martínez‐López

This figure shows the co-authorship network connecting the top 25 collaborators of Joaquín Martínez‐López. A scholar is included among the top collaborators of Joaquín Martínez‐López based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joaquín Martínez‐López. Joaquín Martínez‐López is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Novel Early Memory-Enriched Allogeneic NKG2D CAR-T Cell Therapy Based on CRISPR/Cas9 Technology for Solid Tumors 2025 ·Cancers ·Cristina Aparicio, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Antonio Valeri, Alejandra Leivas, Paula Rı́o, Daniel J. Powell, (unknown), (unknown), Joaquín Martínez‐López, Ana Sánchez, Miguel Á. de la Fuente, Margarita González‐Vallinas	0
2	Osmotic stress influences microtubule drug response via WNK1 kinase signaling 2025 ·Drug Resistance Updates ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Juan Manuel Rosa-Rosa, Joaquín Martínez‐López, Ricardo Sánchez‐Prieto, Rocı́o Sotillo, Guillermo de Cárcer	0
3	Artificial Intelligence Models for Risk Stratification and Prognosis in AML-NOS 2024 ·Blood ·(unknown), Ana Maria Mendoza-Martínez, (unknown), (unknown), (unknown), (unknown), David Bermejo-Peláez, (unknown), (unknown), (unknown), (unknown), María J. Ledesma‐Carbayo, (unknown), (unknown), (unknown), Miguel Luengo-Oroz, Joaquín Martínez‐López	0
4	LONG-TERM FOLLOW-UP FROM THE PHASE 1/2 MAJESTEC-1 TRIAL OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS BY LINES OF THERAPIES 2024 ·Hematology Transfusion and Cell Therapy ·Luciano J. Costa, (unknown), Laura Rosiñol, Rakesh Popat, (unknown), Joaquín Martínez‐López, (unknown), Tara Stephenson, Katherine Chastain, (unknown)	0
5	Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis. 2024 ·Journal of Clinical Oncology ·Luciano J. Costa, Katja Weisel, (unknown), Surbhi Sidana, Yaël C. Cohen, Duncan Purtill, Cyrille Touzeau, Carlos Fernández de Larrea, Joaquín Martínez‐López, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, (unknown), Katherine Li, Martin Vogel, Mythili Koneru, Nitin Patel, Erika Florendo, (unknown), María‐Victoria Mateos	2
6	A machine learning tool for the diagnosis of SARS‐CoV‐2 infection from hemogram parameters 2023 ·Journal of Cellular and Molecular Medicine ·(unknown), Gloria Pérez Segura, (unknown), (unknown), (unknown), José María Aguado, (unknown), (unknown), Joaquín Martínez‐López	2
7	LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE (SOC) AS SECOND‐LINE THERAPY IN LARGE B‐CELL LYMPHOMA (TRANSFORM STUDY): SUBGROUP ANALYSES BY PRIOR THERAPY RESPONSE 2023 ·Hematological Oncology ·Loretta J. Nastoupil, Manali Kamdar, Julio C. Chávez, Hervé Ghesquières, Monalisa Ghosh, Holly E. Holmes, Armando López‐Guillermo, Joaquín Martínez‐López, Urban Novak, Vincent Ribrag, Claire Roddie, Edmund K. Waller, Tatyana Feldman, Allison Rosenthal, Craig S. Sauter, Malte von Bonin, Reem Karmali, Sandrine Montheard, Alessandro Previtali, Jeremy S. Abramson	0
8	Impact of IPSS-M implementation in real-life clinical practice 2023 ·Frontiers in Oncology ·(unknown), (unknown), Rosa Ayala, Inmaculada Rapado, Joaquín Martínez‐López, María‐Teresa Cedena	3
9	Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial 2023 ·Blood ·(unknown), Juan Carlos Hernández‐Boluda, (unknown), María Teresa Gómez‐Casares, Rosa Ayala, Blanca Xicoy, Francisca Ferrer‐Marín, Guillermo Ortí, Raquel De Paz Arias, (unknown), (unknown), Elvira Mora, (unknown), (unknown), Concepción Boqué, (unknown), Joaquín Martínez‐López, Valentín García‐Gutiérrez	1
10	Remission of lupus nephritis: the trajectory of histological response in successfully treated patients 2023 ·Lupus Science & Medicine ·Ana Malvar, Valeria Albertón, Bruno Lococo, Maria Helena Lourenço, Joaquín Martínez‐López, (unknown), (unknown), (unknown), Haikady N. Nagaraja, (unknown), Bethany J. Wolf, Brad H. Rovin	14
11	AL Amyloidosis and Multiple Myeloma: A Complex Scenario in Which Cardiac Involvement Remains the Key Prognostic Factor 2023 ·Life ·(unknown), Isabel Krsnik, Manuel Gómez‐Bueno, Pablo García‐Pavía, Javier Segovia, Ana Huerta, Clara Salas, Ramona A. Silvestre, (unknown), (unknown), Laura Delgado, Juan José Lahuerta, Joaquín Martínez‐López, Rafael F. Duarte	9
12	Comparative Efficacy and Safety of Tisagenlecleucel (tisa-cel) and Axicabtagene Ciloleucel (axi-cel) in Relapsed/ Refractory Follicular Lymphoma (r/r FL) 2022 ·Transplantation and Cellular Therapy ·Michael Dickinson, Joaquín Martínez‐López, (unknown), (unknown), Hongbo Yang, (unknown), (unknown), (unknown), (unknown), Chiara Lobetti‐Bodoni, Stephen J. Schuster, Nathan Fowler	1
13	Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19 2022 ·Biomedicines ·Estéfani García‐Ríos, Alejandra Leivas, Francisco J. Mancebo, (unknown), (unknown), José María Aguado, Joaquín Martínez‐López, (unknown), Pilar Pérez‐Romero	1
14	Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL) 2021 ·Blood ·Franck Morschhauser, Carmelo Carlo‐Stella, Michael Dickinson, Tycel Phillips, Roch Houot, Fritz Offner, Corinne Haïoun, Paolo Corradini, Martin Hutchings, Anna Sureda, Joaquín Martínez‐López, Tomasz Wróbel, Shang‐Ju Wu, Linda Lundberg, (unknown), David Pérez-Callejo, James Relf, Anesh Panchal, Kathryn Humphrey, Emmanuel Bachy	20
15	First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma 2020 ·Clinical Cancer Research ·Ravi Vij, Rajneesh Nath, Daniel Afar, María‐Victoria Mateos, Jesús G. Berdeja, Marc S. Raab, Andreas Guenther, Joaquín Martínez‐López, Andrzej Jakubowiak, Xavier Leleu, Katja Weisel, Shekman Wong, (unknown), James P. Sheridan, Anita Reddy, Bruno Paiva, Anil Singhal, Jesús F. San Miguel, Philippe Moreau	24
16	Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1‐acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group 2020 ·British Journal of Haematology ·Enrique M. Ocio, (unknown), Paula Rodríguez‐Otero, Joaquín Martínez‐López, (unknown), Jesús Martín, Joan Bladé, (unknown), (unknown), Aránzazu García‐Mateo, Felipe de Arriba, Ramón García‐Sánz, Javier de la Rubia, Albert Oriol, Juan José Lahuerta, Jesús F. San Miguel, María‐Victoria Mateos	14
17	Novel DNMT3A Germline Variant in a Patient with Multiple Paragangliomas and Papillary Thyroid Carcinoma 2020 ·Cancers ·(unknown), Javier Pardo de Santayana y Coloma, Bruna Calsina, María Monteagudo, Juan María Roldán‐Romero, María Santos, Luis J. Leandro‐García, Javier Lanillos, Ángel M. Martínez‐Montes, Cristina Rodríguez‐Antona, Cristina Montero‐Conde, Joaquín Martínez‐López, Rosa Ayala, Xavier Matías‐Guiu, Mercedes Robledo, Alberto Cascón	9
18	Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells 2017 ·Clinical Cancer Research ·Lucía Fernández, (unknown), Adela Escudero, María Vela, Jaime Valentín, Isabel Vallcorba, Alejandra Leivas, Juan Manuel Torres, Antonio Valeri, Ana Patiño‐García, Joaquín Martínez‐López, Wing Leung, Antonio Pérez‐Martínez	83
19	Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission 2013 ·Clinical Cancer Research ·Leonor Puchades‐Carrasco, Ramón Lecumberri, Joaquín Martínez‐López, Juan José Lahuerta, María‐Victoria Mateos, Felipe Prósper, Jesús F. San Miguel, Antonio Pineda‐Lucena	70
20	Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival 2008 ·Journal of Clinical Oncology ·Juan José Lahuerta, María‐Victoria Mateos, Joaquín Martínez‐López, Laura Rosiñol, Anna Sureda, Javier de la Rubia, José García‐Laraña, Rafael Martínez-Martinez, Miguel Teodoro Hernández‐Garcia, Dolores Carrera, Joan Besalduch, Felipe de Arriba, Josep‐María Ribera, Lourdes Escoda, (unknown), Javier García‐Frade, (unknown), Adrían Alegre, Joan Bladé, Jesús F. San Miguel	193

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact